A new anti-tumor inhibitor targeting PLK1 PBD

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-A-054-Monday
• By: ZHANG, Jing (Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China)
• Co-author(s): Jing Zhang: Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China
  Yunyu Chen: Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China
  Shuyi Si: Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China
  
• Abstract:

  Backgrounds

  PLKs contain an N-terminal serine/threonine kinase domain and a C-terminal Polo-box region. Due to the conserved nature of the ATP-binding pocket, the drugs that target the kinase domain might not be specific to PLK1. As PBD is unique and a specific signature of the PLK kinase family, targeting the PBD of PLK1 has been postulated as an..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login